Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy-Reference-Cited by-同舟云学术

Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy

Published:2019-03 Issue:2 Volume:1 Page:76-83
ISSN:1478-1239
Container-title:GastroHep
language:en
Short-container-title:GastroHep

Author:

Kozbial Karin¹^ORCID,Al‐Zoairy Ramona²,Gschwantler Michael³,Stauber Rudolf⁴,Hametner Stephanie⁵,Laferl Hermann⁶,Strasser Michael⁷,Hayat‐Khayyati Avida⁸,Datz Christian⁹,Kramer Ludwig¹⁰,Schaefer Benedikt²,Maieron Andreas⁵¹¹,Graziadei Ivo¹²,Stättermayer Albert Friedrich¹,Beinhardt Sandra¹,Munda Petra¹,Zoller Heinz²,Holzmann Heidemarie¹³,Aberle Stephan W.¹³,Trauner Michael¹,Hofer Harald¹¹⁴,Ferenci Peter¹

Affiliation:

1. Department of Internal Medicine III, Division of Gastroenterology and Hepatology Medical University of Vienna Vienna Austria

2. Department of Internal Medicine I Medical University of Innsbruck Innsbruck Austria

3. Department of Internal Medicine IV Wilhelminenspital Vienna Austria

4. Department of Internal Medicine, Division of Gastroenterology and Hepatology Medical University of Graz Graz Austria

5. Department of Internal Medicine IV Ordensklinikum Linz Linz Austria

6. Department of Internal Medicine Kaiser‐Franz‐Josef‐Spital Vienna Austria

7. Department of Internal Medicine I Paracelsus University of Salzburg Austria

8. Department of Internal Medicine II Kepler University Clinics Linz Austria

9. Department of Internal Medicine Krankenhaus Oberndorf, Teaching hospital of the Paracelsus Private Medical University of Salzburg Oberndorf Austria

10. Department of Internal Medicine I Krankenhaus Hietzing Vienna Austria

11. Department of Internal Medicine II University Clinics St. Poelten St. Pölten Austria

12. Department of Internal Medicine Landeskrankenhaus Hall Tirol Austria

13. Center for Virology Medical University of Vienna Vienna Austria

14. Department of Internal Medicine I Klinikum Wels‐Grieskirchen Wels Austria

Publisher

Hindawi Limited

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ygh2.329

Reference29 articles.

1. Drug Approval Package: VOSEVI (sofosbuvir velpatasvir and voxilaprevir).https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195Orig1s000SumR.pdf. Accessed March 11 2018.

2. Drug Approval Package: MAVYRET (glecaprevir and pibrentasvir).https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000SumR.pdf. Accessed March 11 2018.

3. European public assessment report (EPAR) for Maviret.http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004430/human_med_002151.jsp&mxml:id=WC0b01ac058001d124. Accessed March 20 2018.

4. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment

5. Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system;Hepatology;2023-04-03

2. Re: Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus‐infected persons treated with direct‐acting antivirals: Public health impact amongst Swedish cohort in the Covid‐19 pandemic era;GastroHep;2021-07

3. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome;Journal of Viral Hepatitis;2020-11-25

4. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion;Zeitschrift für Gastroenterologie;2020-11

5. Letter: management of patients with chronic hepatitis C failing repeated courses of interferon‐free DAA combination therapy: a translational research perspective with clinical impact;GastroHep;2019-05